Stockscreener 앱 받기
2.12
0.95%
0.02
시간 외 거래:
2.14
0.02
+0.94%
Cassava Sciences Inc 주식(SAVA)의 최신 뉴스
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - earlytimes.in
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Published on: 2025-12-22 08:32:25 - Улправда
Can Cassava Sciences Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to dividend seekersWeekly Earnings Recap & Reliable Price Breakout Alerts - Улправда
How Cassava Sciences Inc. stock responds to policy changesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9%What's Next? - MarketBeat
Will Cassava Sciences Inc. stock benefit from sector rotationQuarterly Investment Review & Real-Time Stock Price Movement Reports - Улправда
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff? - MSN
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Asianet Newsable
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
Cassava Sciences stock falls after FDA places clinical trial on hold By Investing.com - Investing.com South Africa
Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Australia
Cassava Sciences Shares Fall Pre-Bell After FDA Clinical Hold on Simufilam Trial - marketscreener.com
Growth Value: Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationQuarterly Profit Report & Proven Capital Preservation Tips - Улправда
Cassava Sciences down on delay for epilepsy study (SAVA:NASDAQ) - Seeking Alpha
Rate Cut: How Cassava Sciences Inc. stock responds to policy changesEarnings Trend Report & AI Powered Market Trend Analysis - Улправда
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peersDollar Strength & Entry Point Confirmation Signals - DonanımHaber
Is Cassava Sciences Inc. stock a dividend growth opportunityJuly 2025 Review & Community Driven Trade Alerts - DonanımHaber
Why Cassava Sciences Inc. Equity Warrant stock remains undervaluedPortfolio Performance Report & Weekly Return Optimization Plans - Улправда
Cassava Sciences IncOn Dec 15, FDA places full clinical hold on Cassava's trialSEC filing - marketscreener.com
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy By Investing.com - Investing.com South Africa
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy - Investing.com Nigeria
FDA Places Clinical Hold on Cassava’s Epilepsy Trial - TipRanks
Cassava Sciences Receives FDA Clinical Hold on Simufilam Trial - TradingView — Track All Markets
Published on: 2025-12-18 21:27:30 - Улправда
Cassava Sciences (NASDAQ: SAVA) details 2025 executive bonuses and simufilam TSC focus - Stock Titan
Cassava Sciences (SAVA) Stock Analysis Report | Financials & Insights - Benzinga
Cassava Sciences Submits IND Application for Simufilam - MSN
Cassava Sciences rises 10% after market close on CEO stock buy - MSN
Why Cassava Sciences Inc. Equity Warrant stock is rated strong buyDividend Hike & High Accuracy Investment Signals - Newser
Why Cassava Sciences Inc. (PX91) stock appeals to dividend investors2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Why Cassava Sciences Inc. (PX91) stock could be next leader2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Can Cassava Sciences Inc. (PX91) stock deliver double digit returnsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
How Cassava Sciences Inc. Equity Warrant stock compares to industry benchmarksPortfolio Value Summary & AI Forecasted Entry and Exit Points - Newser
2.52%
0.07%
자본화:
|
볼륨(24시간):